Acute (single 500–1000 mg dose): Almost nothing perceivable for most people. Quercetin is not a stimulant or a sedative; the plasma-level dynamics are slow and the targets are anti-inflammatory rather than CNS-stimulant. Some users report mild GI upset within 1–2 hours of a large aglycone dose, especially on an empty stomach.

Sub-chronic (1–4 weeks at 500–1000 mg/day):

• Allergy-prone users (the strongest signal): Reduced histamine load — less sneezing, less ocular itch, less post-exposure congestion. Most reliable in seasonal pollen contexts. Onset usually 5–14 days.
• Athletes: Possible reduction in exercise-induced histamine flush, mild reduction in DOMS in some self-reports. The endurance signal is small to absent in trained adults.
• General users: Most report nothing dramatic. The "energy" and "neuroprotection" reports in the dopamine.club aggregate are likely placebo-heavy or stack-attributed; quercetin alone is not subjectively energizing.

Senolytic pulse (3-day Mayo protocol with dasatinib):

• Not appropriate for biohacker self-experimentation — requires Rx dasatinib and clinical oversight.
• In trial participants, subjective changes during the 3-day pulse are minimal; benefits emerge over weeks.

Characteristic effects (chronic use):

• Mild reduction in seasonal allergy symptom burden (if applicable)
• Modest decrease in resting BP in (pre)hypertensives (1–4 mmHg systolic)
• No detectable cognitive or mood signature
• Possible reduction in uric acid (relevant for hyperuricemia / gout history)

Honest variability: The flat "neutral majority" in repeat-user data is the most honest picture — quercetin is not a "subjectively obvious" supplement. People with seasonal allergies notice it; most others don't.

• Tolerance buildup: Minimal/none documented. Quercetin's mechanisms (NF-κB inhibition, mast-cell stabilization, ACE inhibition, antioxidant defense) are not receptor-occupancy-driven in the classical sense — there's no obvious receptor down-regulation pathway. Long-term safety/efficacy data through 6+ months of daily use shows preserved effect on BP and inflammation markers.
• Recommended cycle: No cycling needed. For allergy use, dose seasonally (high-pollen months) and skip the rest of the year. For cardio support, daily continuous is fine. For senolytic protocols, the 3-days-on / weekly pulse is by design — senescent cells regenerate slowly, so monthly or quarterly pulses (rather than daily) are the proposed clinical model in ongoing trials.
• Reset protocol: Not applicable.
• Cross-tolerance: None documented with other flavonoids or with antihistamines.

Synergistic with

• Bromelain (250 mg with each 500 mg quercetin): Classic "natural antihistamine" stack. Bromelain (pineapple enzyme) may modestly enhance quercetin absorption and adds independent anti-inflammatory effect (fibrinolytic, anti-edema). Quercetin + bromelain capsules are standard format from Solgar, NOW, Thorne, etc.
• Vitamin C (500 mg): Recycles oxidized quercetin back to active form; adds independent antihistamine effect via cofactor role in histamine degradation. The Linus Pauling vitamin-C + quercetin combo is the longest-standing pairing.
• Resveratrol: Adjacent polyphenol with overlapping anti-inflammatory and senescence-modifying mechanisms; both poorly bioavailable as aglycones. The combo is more marketing than evidence, but not contraindicated.
• Fisetin: Related senolytic flavonoid (apples, strawberries). Used at high doses (1.5 g/day, 2 consecutive days/month) in the planned Mayo Clinic senolytic protocols. Not yet RCT-validated in humans for senolytic outcomes. Quercetin + fisetin is a reasonable "polyphenol stack" with redundant rather than additive mechanism.
• Curcumin (already in Dylan's V4): Independent NF-κB inhibitor + COX-2 inhibitor. Complementary anti-inflammatory profile. Both share poor aglycone bioavailability; both benefit from phytosome/Meriva-style formulations.
• NAC (community signal: 119 co-mentions): Cysteine donor / glutathione precursor — pairs with quercetin's Nrf2 induction. Also relevant for the antiviral / COVID-era stack rationale.
• Omega-3 (community signal: 138 co-mentions): Resolvin-pathway synergy on inflammation resolution; no direct interaction.

Avoid stacking with (or use with care)

• Quinolone antibiotics (ciprofloxacin, levofloxacin) — quercetin inhibits bacterial DNA gyrase weakly; theoretically could affect antibiotic activity (mostly speculative).
• High-dose curcumin + quercetin together with iron supplements — both are iron chelators; could compound absorption interference. Separate by 2 hours.
• Levothyroxine — see Drug Interactions; mandatory ≥4-hour separation.

Neutral / safe co-administration

• Magnesium, zinc (separate by 2 hours from quercetin for optimal zinc absorption), vitamin D3, glycine, taurine, L-theanine, creatine, beta-alanine — no interactions documented.
• Most peptides Dylan is using (BPC-157, TB-500, Selank, Semax) — no interaction concern.
• Modafinil — no documented interaction; quercetin's CYP3A4 inhibition is mild and clinically negligible at oral doses, modafinil is mostly amide-hydrolyzed.

Quercetin's metabolic / interaction profile:

• CYP3A4 — moderate inhibitor in vitro; clinically modest in human studies (one caffeine-metabolism study showed "almost negligible" effect). Real-world relevance: minimal at typical supplement doses, but cumulative with other CYP3A4-modifying compounds.
• CYP2C19, CYP2D6 — weaker in vitro inhibition; clinically negligible.
• OATP transporters, BCRP, P-glycoprotein — quercetin inhibits intestinal efflux transporters; can raise plasma levels of drugs that are P-gp/BCRP substrates (digoxin, dabigatran, fexofenadine).
• Quercetin's plasma half-life ~11–12 hours for the glucuronide metabolites; clearance largely renal/biliary.

Clinically significant interactions

1. Warfarin — INCREASED bleeding risk (CAUTION/AVOID)

• Quercetin displaces warfarin from plasma protein binding and inhibits CYP3A4-mediated warfarin clearance. Multiple case reports of elevated INR. Combined with quercetin's mild antiplatelet effect, the bleeding risk is non-trivial.
• Practical rule: Don't combine without explicit physician sign-off and INR monitoring every 1–2 weeks for the first 6 weeks. This applies to apixaban, rivaroxaban, dabigatran similarly (CYP3A4 / P-gp pathway overlap).
• Relevance for Dylan: zero (no anticoagulants).

2. Levothyroxine (Synthroid, Tirosint) — REDUCED absorption (TIMING REQUIRED)

• Quercetin (like calcium, iron, magnesium, soy isoflavones) binds levothyroxine in the gut and reduces absorption. Case reports show TSH creep when quercetin is taken concurrently with morning levothyroxine.
• Practical rule: Take levothyroxine on rising, fasted; wait ≥4 hours before quercetin. Recheck TSH 8 weeks after starting if levothyroxine-dependent.

3. Cyclosporine — INCREASED plasma levels (AVOID without monitoring)

• Quercetin inhibits CYP3A4 + P-gp, both involved in cyclosporine metabolism/efflux. Co-administration can raise cyclosporine levels with nephrotoxicity risk.
• Relevance: transplant patients only.

4. Statins (simvastatin, atorvastatin) — possible mild AUC increase

• CYP3A4 inhibition pathway. Effect modest at typical quercetin doses, but caution at high-dose phytosome use.

5. Tamoxifen — possible reduced efficacy

• Quercetin estrogenic activity is weak; theoretical concern that it could compete at estrogen receptor or affect CYP2D6 activation of tamoxifen. Avoid concurrent use in breast-cancer patients on adjuvant tamoxifen.

6. Fluoroquinolone antibiotics — possible reduced absorption (mild; clinical relevance debated)

7. Calcium-channel blockers (verapamil, diltiazem) — additive BP-lowering effect; usually beneficial but monitor in already-controlled hypertensives.

8. Antiplatelet agents (aspirin, clopidogrel) — quercetin has mild antiplatelet effect; bleeding risk is additive. Caution at high doses (>1 g/day) with chronic aspirin/clopidogrel.

9. CYP3A4 substrates broadly — midazolam, simvastatin, sildenafil, certain calcium-channel blockers may have modestly elevated AUC. Effect size small at typical supplement doses.

10. Caffeine — quercetin is a mild adenosine-receptor modulator; co-administration in one trial showed slight blunting of caffeine's ergogenic effect. Probably trivial in practice.

Quercetin's PGx profile is light — it's a polyphenol with multi-system, low-affinity targets rather than a receptor agonist that pivots on a single genotype.

• COMT Val/Met polymorphism (rs4680): COMT methylates catechol-containing compounds including quercetin and its metabolites. Val/Val (faster COMT) → faster quercetin O-methylation → potentially lower plasma levels of free quercetin metabolites. Met/Met → slower clearance, possibly longer effective duration. Effect size is small and unlikely to drive clinical decisions, but explains some interindividual variability.
• UGT1A polymorphisms: UGT1A1/1A3/1A8/1A9 conjugate quercetin to its glucuronide metabolites. Variants (e.g., UGT1A1*28 — Gilbert syndrome) reduce glucuronidation and could raise free aglycone exposure. Probably benign in supplement context.
• SULT1A1: Sulfates quercetin to monosulfates. SULT1A1*2 genotype reduces activity; possible longer half-life of free quercetin.
• MTHFR C677T: Indirect — methylfolate-dependent COMT activity is reduced in MTHFR-deficient subjects, compounding the COMT effect.
• CYP3A4/3A5: Polymorphism affects extent of any CYP3A4-mediated drug interaction. CYP3A5*3/*3 (non-expressers, ~80% Caucasians) → quercetin's mild 3A4 inhibition matters slightly more.
• SGLT1 (glucose transporter): Quercetin-3-O-glucoside absorption depends on SGLT1 in the intestinal brush border. Genetic variants are rare; clinical relevance minimal.

Dylan-specific: 23andMe results arriving June 2026 will include COMT and MTHFR data via Promethease. Useful tuning info, not a blocker. If COMT Met/Met turns up, quercetin doses can be reduced ~25% and still deliver equivalent metabolite exposure.

For Dylan specifically: Thorne Quercetin Phytosome (250 mg Quercefit) × 60 caps from iHerb, ~$35. Two caps/day during pollen season weeks (March–May, Aug–Oct depending on geography). Skip the cheap aglycone — the phytosome dose is functional, the cheap aglycone at 500 mg twice a day delivers less plasma quercetin than 1 phytosome capsule.

Quality flags:

• Look for Quercefit / Indena licensed on phytosome labels — there are knockoff "phytosome" products with poor characterization.
• For Sophora japonica products, confirm the 3-O-glucoside content is specified.
• Avoid products labeled "quercetin complex" without ingredient detail — usually plain aglycone with marketing.

Sourcing-difficulty rating: easy (OTC, no Rx, widely available, no legal issues in any US state).

Baseline (before starting, if BP-targeted)

• Resting BP (3-day morning average) — only relevant if pre-hypertensive; baseline establishes whether the 2–4 mmHg expected reduction is clinically meaningful for that user.
• Uric acid — if hyperuricemia history, baseline quantifies xanthine-oxidase-inhibition benefit.
• TSH, fT4 if levothyroxine-dependent — establishes thyroid baseline before adding an absorption-modifier.
• CRP / hs-CRP if running for anti-inflammatory rationale — measures whether quercetin moves inflammation markers (signal is mixed in meta-analyses).
• Skin allergy symptom VAS (sneezes/day, congestion 0–10, ocular itch 0–10) for 7 days pre-season — gives a real comparator for symptomatic effect.

During use

• Allergy users: Daily symptom VAS for first 6 weeks of season; expect onset 5–14 days, peak benefit 4–6 weeks.
• BP users: Weekly home BP for first 8 weeks.
• Levothyroxine co-users: TSH at 8 weeks after starting quercetin to confirm no creep.
• Warfarin co-users (if cleared by clinician): INR every 1–2 weeks for first 6 weeks (this is the safety-rails scenario, not a recommendation).

Long-term / chronic use

• Standard annual bloodwork (CBC, CMP, lipids, hs-CRP, TSH). No quercetin-specific monitoring needed at typical supplement doses.

Post-discontinuation

• Allergy users: symptom rebound (or not) over 2–4 weeks confirms whether quercetin was doing real work.
• BP users: BP creep over 4 weeks similar story.